#United States #New York #biopharmaceuticals #Kodiak Sciences #KOD

Kodiak Sciences to Present at Jefferies Global Healthcare Conference 2025

Introduction

On May 29, 2025, Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company focusing on innovative treatments for retinal diseases, announced that its CEO, Victor Perlroth, M.D., will be speaking at the prestigious 2025 Jefferies Global Healthcare Conference. The event is scheduled to take place in New York City on June 5, 2025, at 9:20 AM ET.

This conference gathers industry leaders, investors, and key stakeholders in the healthcare sector, making it an ideal platform for Kodiak to highlight its contributions to retinal disease therapy.

About Kodiak Sciences Inc.

Kodiak Sciences is a pioneering company committed to creating transformative therapeutics. The company aims to tackle a range of retinal diseases through rigorous research and development. Kodiak leverages its proprietary ABC Platform®, which combines protein engineering with chemistry to develop next-generation retina medicines. Their strategies focus on preventing and treating the most common causes of blindness across the globe.

Currently, Kodiak's pipeline showcases three late-phase clinical assets, all gearing towards Phase 3 topline data expected in 2026. These advancements are critical for elevating patient care and capitalizing on emerging therapeutic opportunities.

The 2025 Jefferies Global Healthcare Conference

The Jefferies Global Healthcare Conference is one of the premier events in the healthcare calendar, bringing together experts and advocates from various sectors of the health industry. This year’s conference features notable presentations that aim to inform and engage attendees about the latest innovations and trends in healthcare.

During the presentation, Dr. Perlroth is expected to delve into Kodiak’s current projects, share insights about ongoing clinical trials, and discuss the potential future impact of their therapies on healthcare practices.

A live webcast of the presentation will be available for those unable to attend in person. The webcast can be accessed through the “Events and Presentations” section of Kodiak’s official website. Notably, this session will also be available for replays for a limited period following the event, ensuring wider accessibility to their findings and developments.

Conclusion

As Kodiak Sciences gathers momentum in the biopharmaceutical landscape, their appearance at the Jefferies Global Healthcare Conference represents an opportunity to spotlight their innovative approaches to treating retinal diseases. With a keen focus on advancing science and improving patient outcomes, Kodiak is undoubtedly on a promising path within the biotech arena.

For more updates and detailed information on Kodiak’s initiatives, visit Kodiak Sciences.

Key Takeaways

• - Kodiak Sciences is focused on cutting-edge therapies for retinal diseases.
• - The company is set to present at the Jefferies Global Healthcare Conference on June 5, 2025.
• - Its proprietary ABC Platform® enables groundbreaking approaches in therapeutic design and delivery.